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Abstract
Background: Totally Implantable Access Ports (TIAP) are being extensively used world-wide and
can be expected to gain further importance with the introduction of new neoadjuvant and adjuvant
treatments in oncology. Two different techniques for the implantation can be selected: A direct
puncture of a central vein and the utilization of a Seldinger device or the surgical Venae sectio. It
is still unclear which technique has the optimal benefit/risk ratio for the patient.
Design: A single-center, expertise based randomized, controlled superiority trial to compare two
different TIAP implantation techniques. 100 patients will be included and randomized pre-
operatively. All patients aged 18 years or older scheduled for primary elective implantation of a
TIAP under local anesthesia who signed the informed consent will be included. The primary
endpoint is the primary success rate of the randomized technique. Control Intervention: Venae
Sectio will be employed to insert a TIAP by a surgeon; Experimental intervention: Punction of V.
Subclavia will be used to place a TIAP by a radiologist. Duration of study: Approximately 10 months,
follow up time: 90 days.
Organisation/Responsibility: The PORTAS 2 – Trial will be conducted in accordance with the
protocol and in compliance with the moral, ethical, and scientific principles governing clinical
research as set out in the Declaration of Helsinki (1989) and Good Clinical Practice (GCP). The
C e n t e r  o f  C l i n i c a l  T r i a l s  a t  t h e  D e p a r t m e n t  o f  S u r g e r y ,  U n i v e r s i t y  H o s p i t a l  H e i d e l b e r g  i s
responsible for design and conduct of the trial including randomization and documentation of
patients' data. Data management and statistical analysis will be performed by the independent
Institute for Medical Biometry and Informatics (IMBI), University of Heidelberg.
Trial Registration: The trial is registered at ClinicalTrials.gov (NCT00600444).
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Background
The first implantation of a TIAP was performed and
described by Niederhuber et al. in 1982. Since then the
insertion of a TIAP is a routinely employed technique in
patients who need a safe and permanent venous access for
chemotherapy, parenteral nutrition, recurrent blood sam-
pling or other reasons [1]. This system needs no external
dressing, allows the patient normal physical activity, is
probably less prone to infectious complications and will
minimize the occlusion rate of the catheter compared to
non-totally implantable catheters [1]. TIAPs are being
extensively used world-wide and an increase in the
number of port placements can be expected. In Germany
70233 TIAP inpatient implantations were performed in
2006 (Federal Statistical Office, Wiesbaden, Germany).
The number of TIAP implantations increased constantly at
our Department from 169 in 1997 to 754 in 2007.
Today two different approaches to implant a TIAP are usu-
ally employed. Venae Sectio (VS) of the cephalic vein per-
formed predominantly by surgeons and Puncture of Vena
Subclavia (PVS) performed by interventional radiologists
or surgeons. While most common complications can be
observed with both techniques such as "pinch off" phe-
nomena, kinking or dislocation of the catheter, subcuta-
neous hematoma, nerve palsy and wound infection, there
are specific risks only associated with PVS like pneumo-
and haematothorax [1,2].
Correct placement of the TIAP in the superior Vena Cava
is mandatory for optimal and safe function of the central
venous access. The median success rate of TIAP implanta-
tion via the conventional approach by transsection of the
cephalic vein is 80% in various prospective and retrospec-
tive trials [2]. In contrast PVS achieved a success rate
between 98 to 100%, up to now in retrospective studies
[3-8].
Study design
Aim of study
The comparison of VS performed by a surgeon versus PVS
performed by an interventional radiologist.
Number of patients needed
A review of published literature showed a median primary
success rate of 80% for the VS in retro- and prospective
studies [1,2,9-15]. PVS achieved a median primary success
rate of 99% in various retrospective studies [3-8]. The
group size for double sided testing was calculated with
Simple Interactive Statistical Analysis (SISA) [16]. If the
difference in success rate is 19% (80% vs. 99%) there will
be an 80% chance that a trial involving 100 patients (50
per group) could detect a significant difference at an alpha
level of 5% (Figure 1). We decided to calculate the sample
size on the results of previous studies instead of calculat-
ing the sample size on a defined minimal clinical impor-
tant difference because all mentioned previous studies
showed a consistent median difference of 19%. This offers
the opportunity to test these results the first time in a RCT
setting with an economical sample size.
Eligibility
Inclusion criteria
￿ Benign and malignant diseases which demand a safe
and permanent venous access, e.g. for chemotherapy or
parenteral nutrition
￿ Age 18 years or older
￿ Patients scheduled for primary elective implantation of
TIAP under local anesthesia
￿ Informed consent
Exclusion criteria
￿ Participation in another intervention-trial with interfer-
ence of intervention and outcome of this study
￿ Lack of compliance (assessed by the trial investigator)
￿ Impaired mental state or language problems (Patient is
not able to read German)
￿ Patients with known allergy to contrast agent
Subject withdrawal criteria
￿ At their own request or at request of the legal represent-
ative
￿ If, in the investigator's opinion, continuation of the trial
would be detrimental to the subject's well-being
All withdrawn patients will be reported in the final results
to guarantee maximum transparency.
Consent
Patients who are assigned for port-catheter-system
implantation either at the Department of Radiology or
Surgery, University hospital of Heidelberg, will be
screened for their eligibility and informed about the POR-
TAS 2 trial during a visit prior to treatment. The study pro-
cedure, risks, benefits and data management will be
clarified in detail before the patients are asked to give their
informed consent. After inclusion of the patient his per-
sonal data (height (cm), weight (kg), gender, smoking
customs, Karnowsky-Index (0 – 100%), medication of
immunsuppresion, antibiotics (yes/no), chemotherapy
(yes/no)) will be recorded into the CRF (Table 1).Trials 2008, 9:60 http://www.trialsjournal.com/content/9/1/60
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Randomization and procedures for minimizing bias
Minimizing bias
To achieve comparable groups for known and unknown
risk factors randomization will be performed as unstrati-
fied block randomization with random block sizes in a
1:1 allocation ratio. Allocation to treatment group will be
carried out by the randomization software RITA®[17]. 110
patients will be recruited according to the sample size cal-
culation. Randomization will be performed by a study
nurse of the Clinical Study Center Surgery (KSC) expertise
based to the Department of Surgery for patients in group
A and to the Department of Radiology for patients in
group B. Randomization will be carried out after patient
signed the informed consent. Intervention will be sched-
uled 1–4 days after inclusion depending on the earliest
operation appointment possible.
Minimizing treatment bias
All physicians who participate in this trial will be trained
and updated every 3 months to guarantee comparable
treatment of patients. Special manuals will be used in the
operation and the radiology room to reduce error. The
same TIAP device will be implanted in all patients
(INTRAPORT II Keramic® by Fresenius Kabi). Antibiotic
prophylaxis will only be given to patients with risk for
endocarditis according to the local standards or to
patients scheduled for a chemotherapy < 5 days after
implantation.
Minimizing measurement bias
A study nurse will document and monitor the procedure
in the operating theatre or radiological intervention
room. Blinding is not possible due to the nature of surgery
and the allocation to different departments.
Study treatment
All patients will be positioned on the table in a five degree
reverse Trendelenburg's position. The neck, chest and
shoulders of the patients will be prepared and draped in
the customary sterile manner.
Flowchart according to CONSORT Figure 1
Flowchart according to CONSORT.
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The left V. Subclavia/V. Cephalica will be preferred except
for one of the following cases:
￿ patient suffers from breast cancer on the left side
￿ patient is left-handed
￿ prior evidence that left V. subclavia is closed by a throm-
bosis
￿ patient's wish
￿ patient had port catheter on left side before
According to the allocation the procedure will be contin-
ued:
Intervention-group A (Venae Sectio performed by a surgeon)
Local anesthesia will be infiltrated in sterile fashion into
skin and subcutaneous layer and skin incision will be per-
formed 4 cm inferolaterally over the deltoideo-pectoral
sulcus region. The cephalic vein is to be exposed. The
cephalic vein will be ligated distally and encircled crani-
ally with a reabsorbable suture. The vein will be cross-
sected ventrally and the catheter flushed with heparinized
saline, then introduced (figure 2, 3). The introduction of
the catheter may be supported by use of a guiding wire,
vein dilatator and peel away sheath if necessary. After
placement of the catheter the correct positioning will be
controlled via fluoroscopy (tip of catheter in the V. cava
superior just to the tune of the bronchial bifurcation). The
catheter will be connected to the port chamber. Using the
same incision, a subcutaneous pocket will be prepared on
the pectoral fascia. The port chamber will be fixed on the
fascia of the pectoral muscle with three single non absorb-
able sutures. The wound will be closed with an absorbable
subcutaneous suture and skin will be closed by a non
absorbable intracutaneous suture. Unhindered flow for
blood withdrawal and infusion is verified by cutaneous
puncture (Huber needle). To complete the procedure the
system is blocked with 2–4 ml heparinized saline (100
I.E./ml).
Intervention-group B (Punction of V. Subclavia by a radiologist)
Patients receive a peripheral venous catheter on the side of
planned puncture location for the administration of con-
Table 1: Study visit schedule
Follow-up
Day of screening Day of operation Visit 1 (day 90 post OP) by phone
Past medical history* X
Informed consent X
Personal data** X
Examination of primary endpoints:
• Success of randomized implantation technique X
Examination of secondary endpoints:
• Peri- and postoperative complications X X
• Times of port implantation procedure X
• Dose of radiation X
Savety criteria AE, SAE (2.6) X X
* study-relevant past medical history, past surgical history
** height (cm), weight (kg), gender, smoking customs, Karnowsky-Index, medication of immunsuppresion, antibiotics, chemotherapy
Venae Sectio – Incision of Cephalic vein Figure 2
Venae Sectio – incision of cephalic vein.Trials 2008, 9:60 http://www.trialsjournal.com/content/9/1/60
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trast agent (Ultravist® 370 by Bayer) and the verification
that the V. subclavia is not closed by thrombosis (road-
map technique, figure 4). Local anesthesia will be intro-
duced in sterile fashion into skin and periost of the clavic-
ula. Location of the puncture will be marked between
proximal and medial third of the clavicula (figure 5). A ca.
2 cm wide skin incision will be performed above puncture
location. In the following the V. Subclavia is punctured
under fluorscopy using the Seldinger technique and a
guiding wire is introduced (figure 6, 7). An introducer
sheath is passed via the guiding wire into the V. subclavia.
The guiding wire is removed and the port catheter may be
introduced through the introducer sheath. Correct posi-
tion is verified by fluoroscopy. A second ca. 3,5 cm wide
skin incision is performed 1 cm below the first incision
parallel to the clavicula. A subcutaneous pocket will be
prepared on the pectoral fascia. The port chamber will be
fixed on the fascia of the pectoral muscle with three single
non absorbable sutures. The wound will be closed with an
absorbable subcutaneous suture and skin will be closed
by a non absorbable intracutaneous suture. Correct posi-
tion of port catheter is checked again by fluorscopy (Tip of
catheter in the V. cava superior just to the tune of the bron-
chial bifurcation). Flow for blood withdrawal and infu-
sion is tested via cutaneous puncture (Huber needle). To
complete the procedure the system is blocked with 2–4 ml
heparinized saline (100 I.E./ml).
Venae Sectio – Introducing of TIAP catheter Figure 3
Venae Sectio – introducing of TIAP catheter.
Puncture of V. Subclavia – Demonstration of V. Subclavia  with contrast agent Figure 4
Puncture of V. Subclavia – demonstration of V. Sub-
clavia with contrast agent.
Puncture of V. Subclavia – Puncture Figure 5
Puncture of V. Subclavia – puncture.
Puncture of V. Subclavia – Introducing guiding wire (Seldinger  technique) Figure 6
Puncture of V. Subclavia – introducing guiding wire 
(Seldinger technique).Trials 2008, 9:60 http://www.trialsjournal.com/content/9/1/60
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Primary and secondary endpoints
Primary endpoint
The primary endpoint will be the success rate of the rand-
omized implantation technique.
Definition of the primary endpoint
Primary success is defined as the correct position of the
catheter in the V. Cephalica/V. Subclavia on the intended
side controlled intraoperatively by radiography and cor-
rect function verified by drawing blood and infusion of
fluid.
Assessment of the primary endpoint
The primary success will be assessed postoperatively by
the responsible physician in the case report file (CRF) and
will be confirmed by an independent study nurse and will
be compared to the operation report. A copy of the intra-
operative radiography showing the right position of the
catheter will be saved in the digital radiological picture
viewer software Centricity®- used routinely by the Univer-
sity Hospital of Heidelberg.
Secondary endpoints
Perioperative complications
￿ pneumothorax
￿ hematothorax
￿ intraoperative lesion of nerves
￿ dislocation of the catheter or the port chamber
￿ intolerance of contrast agent
Postoperative complications
￿ thrombosis
￿ postoperative bleeding
￿ hematoma
￿ disconnection or breakage of the catheter
￿ extravasation of injected fluid
￿ wound infection
￿ cutaneous necrosis
Definitions are shown in Table 2 and Table 3
Assessment
1. Perioperative complications of port implantation will
be recorded with tick boxes at day of operation by an inde-
pendent study nurse.
2. Postoperative complications of port implantation will
be recorded with tick boxes at day of operation and visit 1
(90 days after operation) after a standardized telephone
interview by a study nurse. A confirmation by the respon-
sible family physician will be requested by any abnormal-
ity reported by the patient.
The duration of port implantation procedure
Puncture of V. Subclavia – Introducing peel away sheath Figure 7
Puncture of V. Subclavia – introducing peel away 
sheath.
Table 2: Definitions of perioperative complications.
Pneumothorax Radiological findings
Hematothorax Radiological findings or sonografic findings
Intraoperative lesion of nerves Clinical diagnosis or EMG findings
Dislocation of the catheter or the port chamber Radiological finding
Intolerance of contrast agent Any allergic reaction of contrast agent which requires any application of drugsTrials 2008, 9:60 http://www.trialsjournal.com/content/9/1/60
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￿ Time from first skin incision to last knot of intracutane-
ous suture
￿ Time from patient entering until patient leaving inter-
vention room
Assessment
Both times are recorded by an independent study nurse in
the CRF at the day of operation.
Dose of radiation
Definition: Product of dose rate and surface of radiation
(Gy × cm2).
Assessment
The value will be copied from the display of the used radi-
oscopy device by a study nurse and recorded in the CRF.
Safety aspects
Specification of safety variables
Training for surgeons
For surgeons/radiologists and tutors (senior surgeons/
radiologists) who operated 25 or fewer ports so far the
exact number of operated ports will be noted in the CRF.
Surgeons and tutors (senior surgeons) who have per-
formed more than 25 port operations so far will be classi-
fied in one of the following categories: 26–30; 31–35; 36–
40; 41–45; 46–50; > 50 operated ports and recorded in the
CRF.
Concomitant medication
Concomitant medication will not be recorded because the
primary success rate of the two implantation techniques is
a local and technical endpoint. Therefore, a systemic phar-
macological interaction with the medication of the
patient will be very unlikely.
Past medical history
Prior and concomitant illness of the patients will be doc-
umented in the CRF. The category of the primary disease
(reason for port-catheter implantation) is one of the vari-
ables to be analyzed for baseline comparability.
Adverse events and serious adverse events
AEs will be reported to the principal investigator in regular
intervals during the course of the study. Symptoms antic-
ipated by chemotherapy and progression of malignant ill-
ness will not be recorded as AEs as they are not likely
related to the surgical implantation technique.
SAEs which meet one of definitions of the secondary end-
points are treated as SAEs regarding their documentation
but do not have to be reported to the sponsor (University
Hospital of Heidelberg) and principal investigator (Prof.
Dr. MW Büchler, Chairman of the Department of General,
Visceral and Transplantation Surgery, University Hospital
of Heidelberg) within 24 h. They will be reported to the
principal investigator in regular intervals throughout the
Table 3: Definitions of postoperative complications.
Thrombosis Sonographic findings or phlebography
Postoperative bleeding Clinical diagnosis during reoperation
Hematoma Clinical diagnosis, no reoperation necessary
Disconnection or breakage of the catheter Radiological findigs, findings after explantation
Extravasation of injected fluid Radiological findings or clinical diagnosis
Wound infection Clinical diagnosis. Reopening of wound necessary or antibiotic treatment.
Catheter sepsis Two or more of the following symptoms:
• temperature over 38.3°C or under 36°C
• heart frequency over 90 beats per minute
• breath frequency over 20 breaths per minut, PaCO2 < 32 mmHg (spontan breathing) 
or PaO2/FiO2 < 200 mmHg (mechanical ventilation)
• Total peripheral WBC count > 12 G/L or WBC < 4.0 G/L or > 10% immature 
neutrophils (bands), regardless of total peripheral WBC count
• Plasma C-reactive protein > 2 SD above normal value
AND
Positive findings in bacteriology of the Port catheter pike
Cutaneous necrosis Clinical diagnosis or histological findingTrials 2008, 9:60 http://www.trialsjournal.com/content/9/1/60
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study. The surgical and radiological trial coordinator will
also cross check the SAEs/AEs of all patients.
Analysis
Comparisons will be made of the primary endpoints of
both intervention groups for all randomized patients who
underwent surgery for TIAP implantation. Patients will be
analyzed as randomized. This is in line with the intention-
to-treat principle [18]. In addition, a per-protocol analysis
will be performed.
The outcome measures of the primary endpoint will be
tested for significance with the chi-square test with conti-
nuity correction. Fisher's exact test will be used instead if
one or more expected cell counts are less than five. No
stratification will be used. The estimated odds ratio of pri-
mary success will be presented together with a 95% confi-
dence interval. A secondary analysis will be performed
using a multiple regression model including treatment
group, age, body mass index, surgeon's experience and
Karnofsky Index as predictors. All predictors except for
treatment group will be used as continuous variables.
Patients with missing information regarding primary suc-
cess will be considered as failures in all analyses of pri-
mary success except for one sensitivity analysis in which
these patients will be excluded.
All statistical analyses will be performed using SAS® soft-
ware, Version 9.1 (or higher) of the SAS System for Unix
(SAS Institute Inc., Cary, NC, USA).
Study organization
All patients scheduled for a primary TIAP system implan-
tation procedure in the Outpatient-Clinic of the Depart-
ment of Surgery or Radiology, University Hospital of
Heidelberg, will be referred to and screened by members
of the Clinical Study Center Surgery (KSC). The result of
the screening will be recorded in the screening-log.
Approximately 700 patients per year undergo a TIAP sys-
tem implantation at the Outpatient-Clinic of the Depart-
ment of Surgery and Radiology at the University of
Heidelberg. The estimated time frame to randomize 110
patients will be approximately 6 months.
Sponsor of the PORTAS 2 trial is the University Hospital
of Heidelberg.
The independent data management and statistical analy-
sis will be carried out by the Institute of Medical Biometry
and Informatics (IMBI) of the University of Heidelberg
according to a prespecified Statistical Analysis Plan.
The principal investigator has the right to terminate the
trial and to remove all trial material from the trial centre
at any time in consultation with the Clinical Study Team
Leader and the Biostatistician. Reasons that may require a
termination of the trial include the following:
￿ The incidence or severity of adverse events in this trial
indicates a potential health hazard caused by the study
treatment
￿ It appears that patient's enrolment is unsatisfactory with
respect to quality or quantity or data recording is severely
inaccurate or incomplete
￿ External evidence that renders the necessity to terminate
the trial
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